Last reviewed · How we verify

Incruse Ellipta — Competitive Intelligence Brief

Incruse Ellipta (UMECLIDINIUM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic. Area: Respiratory.

marketed Anticholinergic Muscarinic acetylcholine receptor M4 Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Incruse Ellipta (UMECLIDINIUM) — Glaxo Grp England. Umeclidinium works by blocking the M4 muscarinic acetylcholine receptor to relax airway smooth muscle and improve breathing.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Incruse Ellipta TARGET UMECLIDINIUM Glaxo Grp England marketed Anticholinergic Muscarinic acetylcholine receptor M4 2013-01-01
Pentam PENTAMIDINE Fresenius Kabi marketed Antiprotozoal Muscarinic acetylcholine receptor M4 1984-01-01
Antrenyl OXYPHENONIUM Novartis marketed oxyphenonium Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M4 1982-01-01
Methylrosaniline Chloride GENTIAN VIOLET marketed Muscarinic acetylcholine receptor M4 1982-01-01
Salagen PILOCARPINE marketed Cholinergic Receptor Agonist Muscarinic acetylcholine receptor M4 1974-01-01
Cephadol DIPHENIDOL marketed Antiemetic Muscarinic acetylcholine receptor M4 1967-01-01
Pro-Banthine PROPANTHELINE marketed Anticholinergic Muscarinic acetylcholine receptor M4 1953-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic class)

  1. · 4 drugs in this class
  2. Pearl Therapeutics, Inc. · 3 drugs in this class
  3. Shionogi · 2 drugs in this class
  4. Ain Shams University · 1 drug in this class
  5. Astellas Pharma Inc · 1 drug in this class
  6. Boehringer Ingelheim · 1 drug in this class
  7. Covis · 1 drug in this class
  8. Forest Labs Inc · 1 drug in this class
  9. Fougera Pharms · 1 drug in this class
  10. Glaxo Grp England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Incruse Ellipta — Competitive Intelligence Brief. https://druglandscape.com/ci/umeclidinium. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing